TianTi Biotherapeutics
Next-gen biotech developing therapeutic antibodies using proprietary single cell microfluidics and yeast display systems
About TianTi Biotherapeutics
TianTi Biotherapeutics is a preclinical stage biotech company specializing in the development of therapeutic antibodies. The company leverages proprietary single cell microfluidics and yeast display systems to fundamentally change the way antibodies are made. TianTi Bio focuses on oncology and rare disease indications, aiming to deliver fast, high-quality results for challenging targets. By combining rigorous data analysis and teamwork, the company generates a greater number of differentiated antibodies, providing a strong basis for intellectual property protection. TianTi Biotherapeutics operates labs in Greater Boston, MA, and Suzhou, China, and collaborates with multidisciplinary teams and industry partners to pioneer visionary new medicines globally. The business model revolves around preclinical research and development, targeting pharmaceutical companies and research institutions as primary clients. Revenue is generated through partnerships, licensing agreements, and potential future product sales.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Open positions
- None listed
- Dealroom signal
- 21.0/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotechnology, Microfluidics, Disease, Biotech and Pharma, DT and LS, science-based
- Technology
- Artificial Intelligence
- Business model
- Manufacturing
- Client focus
- B2B
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Dec 2021 | $14M | $55M | Oriza Holdings · Yuexiu Industrial Fund · Shanghai Biomedical Innovation and Transformation Fund · Kaitai Capital | ↗ |
| OtherOther financing | May 2021 | $0 | — | Cathay Capital | ↗ |
Growth signals
Latest recorded traffic for TianTi Biotherapeutics is 350 monthly website visits, up 1066.7% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
TianTi Biotherapeutics in the Suzhou Shi ecosystem
The TianTi Biotherapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
Oriza Holdings- YFYuexiu Industrial Fund
- SFShanghai Biomedical Innovation and Transformation Fund
- KCKaitai Capital
Other known investors1 additional known investor
Cathay Capital
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about TianTi Biotherapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See TianTi Biotherapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










